CARGO Therapeutics, Inc. (CRGX) has been on a downward spiral lately with significant selling pressure. After declining 14.1% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting ...

A downtrend has been apparent in CARGO Therapeutics, Inc. (CRGX) lately. While the stock has lost 5.9% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the fu ...

Financial Performance - The company reported a net loss of $41.9 million for the three months ended September 30, 2024, compared to a net loss of $35.5 million for the same period in 2023, reflecting an increase of $6.4 million [81]. - The company had an accumulated deficit of $267.2 million as of September 30, 2024 [81]. - The company expects to continue incurring significant net operating losses as it advances product candidates through clinical development and seeks regulatory approvals [81]. - The company has not generated any revenue from product sales since inception and does not expect to do so until regulatory approval is obtained for its product candidates [82]. - Cash used in operating activities for the nine months ended September 30, 2024, was $104.9 million, primarily due to a net loss of $122.1 million [114]. - Cash used in operating activities for the nine months ended September 30, 2023, was $52.2 million, attributed to a net loss of $66.1 million [115]. - The company may need to raise substantial additional capital to continue operations and achieve profitability [112]. Expenses - Research and development expenses increased to $35.9 million for the three months ended September 30, 2024, up from $22.2 million in the same period of 2023, representing a rise of $13.7 million [96]. - General and administrative expenses rose to $11.2 million for the three months ended September 30, 2024, compared to $6.5 million in the prior year, an increase of $4.7 million [96]. - Total operating expenses for the three months ended September 30, 2024, were $47.1 million, up from $28.7 million in the same period of 2023, marking an increase of $18.4 million [96]. - For the nine months ended September 30, 2024, research and development expenses totaled $103.9 million, a significant increase of $55.2 million from $48.7 million in 2023 [103]. - General and administrative expenses for the nine months ended September 30, 2024, were $33.3 million, up $20.3 million from $13.0 million in 2023 [104]. - The increase in research and development expenses was primarily driven by a $24.8 million rise in manufacturing and technical operations costs for the nine months ended September 30, 2024 [103]. Cash and Liquidity - Cash and cash equivalents, along with marketable securities, totaled $404.8 million as of September 30, 2024, expected to be sufficient to meet working capital needs through 2026 [81]. - The company anticipates that its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs through 2026 [110]. - Cash flows for the nine months ended September 30, 2024, resulted in a net decrease in cash and cash equivalents of $334.6 million [113]. - Total fixed lease payment obligations outstanding as of September 30, 2024, are $45.3 million, with $3.1 million payable within the next 12 months [119]. - The company has entered into lease arrangements for facilities through March 31, 2031, impacting future liquidity and cash flows [119]. Financing Activities - Cash provided by financing activities for the nine months ended September 30, 2024, was $103.6 million, consisting of $102.9 million in net proceeds from the issuance of common stock [117]. - The company expects to fund operations through public or private equity offerings or debt financings until significant product revenue is generated [112]. Clinical Development - The company is advancing its lead program, firicabtagene autoleucel (firi-cel), in a potentially pivotal Phase 2 clinical trial for patients with large B-cell lymphoma (LBCL) who are refractory to CD19 CAR T-cell therapy [79]. - The company is developing CRG-023, a tri-specific CAR T designed to target multiple B-cell lineage antigens, aiming to provide durable responses for a broader range of B-cell malignancies [79]. - Interest income surged to $5.4 million for the three months ended September 30, 2024, up from $0.9 million in 2023, reflecting a $4.5 million increase due to higher cash balances [99]. - Interest income for the nine months ended September 30, 2024, reached $15.4 million, a $13.8 million increase from $1.6 million in 2023 [105].

Clinical Trials - 57 patients have been dosed in the FIRCE-1 Phase 2 clinical study of firi-cel, with interim analysis expected in 1H25[1] - The Independent Data Monitoring Committee recommended the continuation of the FIRCE-1 study without modification[3] - CARGO anticipates submitting the IND application for CRG-023 in Q1 2025, with the first patient dosed planned for 2025[4] - CARGO will present pre-clinical data for CRG-023 at the ASH 2024 meeting, highlighting its durable anti-tumor activity[4] Financial Performance - Research and Development (R&D) expenses for Q3 2024 were $35.9 million, compared to $22.2 million in Q3 2023, representing a 61.6% increase[5] - General and Administrative (G&A) expenses for Q3 2024 were $11.2 million, up from $6.5 million in Q3 2023, a 72.5% increase[5] - Net loss for Q3 2024 was $41.9 million, or $0.88 per share, compared to a net loss of $35.5 million, or $0.47 per share in Q3 2023[5] - Total operating expenses for Q3 2024 were $47.1 million, compared to $28.7 million in Q3 2023, a 64% increase[8] Cash Position - Cash, cash equivalents, and marketable securities as of September 30, 2024, totaled $404.8 million, sufficient to fund operations through 2026[5] Leadership Changes - Anup Radhakrishnan has been appointed as COO in addition to his role as CFO, enhancing operational leadership[2]

Along with quarterly results, the clinical-stage company provided an encouraging business update. This was a good week to be invested in clinical-stage biotech Cargo Therapeutics (CRGX 1.04%). The company dropped its second-quarter earnings release, and investors were quite cheered by the progress the business is making. They also liked that its net loss for the period wasn't as deep as analysts expected. Across the five trading days, Cargo's stock price rose by just under 19%, according to data compiled by ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to ____________ Commission File Number: 001-41859 CARGO Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-40 ...

Exhibit 99.1 CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., August 12, 2024 – CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, poten ...

SAN CARLOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that The Lancet has published favorable data from a Phase 1, single-center clinical study (NCT04088890) by Stanford Medicine (Stanford), evaluating firi-cel, a CD22 CAR T-cell therapy CARGO in-licensed for patients with LBCL whose disease is R/R to CD19 CAR Tcell the ...

– Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Jane Pritchett Henderson to its Boa ...

– Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Jane Pritchett Henderson to its Boa ...